Novocure Ltd (NVCR) CEO Sells $335,655.48 in Stock

Novocure Ltd (NASDAQ:NVCR) CEO Asaf Danziger sold 13,974 shares of Novocure stock in a transaction on Monday, January 29th. The stock was sold at an average price of $24.02, for a total value of $335,655.48. Following the completion of the sale, the chief executive officer now directly owns 356,790 shares of the company’s stock, valued at approximately $8,570,095.80. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Asaf Danziger also recently made the following trade(s):

  • On Wednesday, January 24th, Asaf Danziger sold 20,848 shares of Novocure stock. The stock was sold at an average price of $22.10, for a total value of $460,740.80.
  • On Tuesday, January 16th, Asaf Danziger sold 14,900 shares of Novocure stock. The stock was sold at an average price of $22.20, for a total value of $330,780.00.
  • On Friday, January 12th, Asaf Danziger sold 336,420 shares of Novocure stock. The stock was sold at an average price of $22.33, for a total value of $7,512,258.60.
  • On Monday, November 6th, Asaf Danziger sold 6,919 shares of Novocure stock. The stock was sold at an average price of $22.00, for a total value of $152,218.00.
  • On Friday, November 3rd, Asaf Danziger sold 2,300 shares of Novocure stock. The stock was sold at an average price of $22.00, for a total value of $50,600.00.

Shares of Novocure Ltd (NASDAQ:NVCR) traded up $0.50 on Thursday, hitting $21.05. The company had a trading volume of 585,600 shares, compared to its average volume of 937,617. The company has a quick ratio of 5.30, a current ratio of 5.90 and a debt-to-equity ratio of 0.83. Novocure Ltd has a one year low of $6.75 and a one year high of $24.15. The company has a market capitalization of $1,880.00 and a price-to-earnings ratio of -25.36.

NVCR has been the subject of a number of research analyst reports. Wedbush reissued an “outperform” rating and issued a $25.00 target price (down previously from $29.00) on shares of Novocure in a report on Friday, October 27th. Zacks Investment Research raised Novocure from a “hold” rating to a “buy” rating and set a $23.00 target price for the company in a report on Wednesday, January 3rd. JPMorgan Chase & Co. reaffirmed a “buy” rating on shares of Novocure in a report on Monday, November 20th. BidaskClub raised Novocure from a “hold” rating to a “buy” rating in a report on Saturday, January 13th. Finally, ValuEngine raised Novocure from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $21.13.

Several institutional investors and hedge funds have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its position in Novocure by 6,617.7% during the second quarter. Goldman Sachs Group Inc. now owns 4,988,007 shares of the medical equipment provider’s stock valued at $86,293,000 after purchasing an additional 4,913,755 shares in the last quarter. FMR LLC lifted its position in Novocure by 50.4% during the second quarter. FMR LLC now owns 6,888,120 shares of the medical equipment provider’s stock valued at $119,165,000 after purchasing an additional 2,309,559 shares in the last quarter. Vanguard Group Inc. lifted its position in Novocure by 40.5% during the second quarter. Vanguard Group Inc. now owns 4,283,862 shares of the medical equipment provider’s stock valued at $74,111,000 after purchasing an additional 1,235,922 shares in the last quarter. Farallon Capital Management LLC purchased a new position in Novocure during the fourth quarter valued at $23,533,000. Finally, Tamarack Advisers LP purchased a new position in Novocure during the fourth quarter valued at $21,311,000. 42.02% of the stock is owned by institutional investors.

WARNING: This story was first published by Week Herald and is the sole property of of Week Herald. If you are viewing this story on another website, it was copied illegally and reposted in violation of US & international trademark and copyright legislation. The original version of this story can be accessed at https://weekherald.com/2018/02/15/insider-selling-novocure-ltd-nvcr-ceo-sells-13974-shares-of-stock.html.

Novocure Company Profile

NovoCure Limited is a commercial-stage oncology company. The Company is engaged in developing a cancer treatment centered on a therapy called TTFields, the use of electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. Its TTFields delivery system is used for the treatment of glioblastoma (GBM) and to advance programs testing of TTFields in multiple solid tumor indications through its clinical pipeline.

Insider Buying and Selling by Quarter for Novocure (NASDAQ:NVCR)

Receive News & Ratings for Novocure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novocure and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply